FDA Grants Accelerated Approval to BMS’s CELMoD Zenbexus in Quadruple Therapy for Relapsed/Refractory Multiple Myeloma

August 17, 2026

Drugs.com, FDA.gov USA

Overview

The U.S. FDA has granted accelerated approval to Bristol Myers Squibb’s cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with relapsed/refractory multiple myeloma who have received at least one prior proteasome inhibitor and an immunomodulatory agent. This quadruple therapy offers a new, promising option for patients with limited treatment alternatives, demonstrating significant clinical benefit by inducing targeted protein degradation.

In Depth

Key Findings

On August 13, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a quadruple combination therapy featuring Bristol Myers Squibb’s (BMS) cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide). This regimen, which also includes daratumumab, hyaluronidase-fihj, and dexamethasone, is approved for adult patients with relapsed or refractory multiple myeloma who have previously received at least one proteasome inhibitor and one immunomodulatory agent. This approval marks a significant advancement in treating a challenging patient population.

Technical / Clinical Details

Zenbexus is a novel small molecule drug that operates through a targeted protein degradation (TPD) mechanism. It modulates the cereblon (CRBN) E3 ubiquitin ligase complex, leading to the degradation of specific proteins essential for multiple myeloma cell survival and proliferation. Clinical trials supporting this accelerated approval indicated a high response rate and a favorable safety profile in the pre-treated patient cohort, suggesting a meaningful clinical benefit for those resistant to existing therapies. This mechanism offers a distinct advantage over traditional immunomodulatory drugs (IMiDs) by providing a different protein degradation profile, potentially overcoming established resistance pathways.

Background & Context

Multiple myeloma is an incurable hematologic malignancy characterized by recurrent relapses and the development of resistance to therapies. There remains a critical need for new treatment options for patients whose disease has progressed despite multiple lines of therapy. CELMoDs like Zenbexus represent a new generation of IMiDs, designed to induce the degradation of specific proteins, offering a novel strategy to combat drug resistance and improve outcomes in this difficult-to-treat cancer. This approval underscores the increasing importance of TPD in oncology and the diversification of therapeutic approaches for hematological malignancies.

Strategic Significance & Outlook

The accelerated approval of Zenbexus is expected to significantly impact the treatment landscape for relapsed/refractory multiple myeloma, offering patients access to a powerful new regimen that can induce deeper and more durable responses. As per the accelerated approval pathway, BMS is obligated to conduct further confirmatory trials to verify the clinical benefit. The successful introduction of Zenbexus is anticipated to not only improve patient prognosis but also spur further research and development of TPD-inducing agents for other hematological and solid tumor indications, solidifying this modality’s role in future cancer treatment.

Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.